Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14559281 | 1.00 | KIF11 (0.44) | KIF11KCNN4TAAR1HTR2AMAPK1 | |
| SCHEMBL569600 | 1.00 | KIF11 (0.44) | KIF11KCNN4TAAR1HTR2AMAPK1 | |
| SCHEMBL7479981 | 0.88 | KCNN4 (0.43) | KIF11KCNN4MAPK1KDM4ELMNA | |
| SCHEMBL3302423 | 0.81 | KCNN4 (0.47) | KIF11KCNN4KDM4ELMNA | |
| SCHEMBL3856980 | 0.81 | KCNN4 (0.47) | KIF11KCNN4KDM4ELMNA | |
| SCHEMBL2490293 | 0.81 | KCNN4 (0.38) | KIF11KCNN4MAPK1KDM4ECYP3A4 | |
| SCHEMBL3302429 | 0.81 | KCNN4 (0.47) | KIF11KCNN4KDM4ELMNA | |
| SCHEMBL5794635 | 0.80 | MAPK1 (0.47) | MAPK1KDM4ELMNACYP3A4 | |
| SCHEMBL2029205 | 0.80 | MAPT (0.37) | KIF11KCNN4MAPK1KDM4ELMNA | |
| SCHEMBL2032169 | 0.80 | MAPT (0.37) | KIF11KCNN4MAPK1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993544-B2 | Carbamoylphosphonates as inhibitors and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2015-03-31 | — | — | US | disclosed |
| EP-2393495-B1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RES DEV CO (IL) | 2014-07-23 | — | — | EP | disclosed |
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2012-02-09 | — | — | US | disclosed |
| EP-2393495-A1 | CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089752-A1 | CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | MMP9, MMP26, MMP25 | KIF11 3836/4885KCNN4 3159/4885TAAR1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.